A Study to Assess Tolerability, Safety, Pharmacokinetics and Effect of AZP2006 in Patients With PSP
A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Assess Tolerability, Safety, Pharmacokinetics and Effect of AZP2006 on Cerebrospinal Fluid Biomarkers in 36 Patients With Progressive Supranuclear Palsy
A phase 2 study to assess tolerability, safety, pharmacokinetics and effect of AZP2006 at different doses versus placebo on cerebrospinal fluid biomarkers in 36 patients with progressive supranuclear palsy. The patient study duration is 29 weeks including a washout period.
Number and percentage of patients who prematurely discontinue from the study due to adverse events (AEs)
Progressive Supranuclear Palsy
AZP2006 oral solution
Study Arms / Comparison Groups
Description: Patients randomized in this arm will receive 60 mg of study investigational drug AZP2006 once daily during 84 days.
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
June 22, 2020
July 18, 2022
Primary Completion Date
July 18, 2022
Inclusion Criteria: - Male and female patients with probable or possible PSP - Patients must be stable with their medication for at least 30 days prior to the inclusion visit. Exclusion Criteria: - Any history of clinically significant head trauma or cerebrovascular disease or recent history of substance abuse or alcohol abuse and deemed to be clinically significant by the Investigator. - History of deep brain stimulator (DBS) surgery other than sham surgery for DBS clinical study.
40 Years - 80 Years
Accepts Healthy Volunteers
Philippe Verwaerde, PhD, ,
Philippe Verwaerde, PhD, Study Director, AlzProtect SAS